Intech Investment Management LLC Has $1.90 Million Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Intech Investment Management LLC lifted its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 78.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 110,756 shares of the biotechnology company’s stock after buying an additional 48,636 shares during the period. Intech Investment Management LLC’s holdings in ADMA Biologics were worth $1,899,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of ADMA. State Street Corp boosted its stake in shares of ADMA Biologics by 61.4% in the 3rd quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock valued at $259,970,000 after purchasing an additional 4,945,063 shares in the last quarter. Geode Capital Management LLC boosted its position in ADMA Biologics by 2.6% in the third quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company’s stock valued at $107,606,000 after buying an additional 137,989 shares in the last quarter. Perpetual Ltd bought a new stake in shares of ADMA Biologics during the fourth quarter worth $62,300,000. Lord Abbett & CO. LLC acquired a new position in shares of ADMA Biologics during the third quarter worth $61,858,000. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of ADMA Biologics by 1,144.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock worth $51,016,000 after buying an additional 2,613,482 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Stock Down 4.7 %

ADMA stock opened at $19.65 on Friday. The stock’s 50 day simple moving average is $16.74 and its 200 day simple moving average is $18.01. The company has a market cap of $4.65 billion, a P/E ratio of 70.18 and a beta of 0.60. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $23.64.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.